Events

NATO - DIANA Defence and Security Days
FEB
Wed
05
FEB
Thu
06

Starts in 10 hours ago

Location

Krakow, Poland

ICE Krakow Congress Centre
Programmes
Defence NATO-EDA

Attachments

There are 2 attachments connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The DIANA Defence and Security Days, an event aiming to foster collaboration among innovators and experts, provide insights into cutting-edge developments and create valuable networking opportunities for distinguished guests from across the Alliance.  

This would be a great opportunity to engage in-person with the 74 start-ups from DIANA’s 2nd cohort

 

Date: Wednesday 5, and Thursday, 6 February 2025 

Location: Krakow, Poland  

Venue: ICE Krakow Congress Centre 

  

Agenda is attached when you view this event on the NCP Flanders website   

 

To confirm your attendance, you can register here.   

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.